Therapeutic development starts in the cell

We’ve designed an innovative workflow to unlock the potential of single-cell genomics.

Be part of what’s next

Technology to empower the single-cell revolution

Single-cell genomics has the potential to advance clinical research and diagnostics development, but existing sample preparation workflows are complex and cost-prohibitive, limiting its applications, therefore limiting its impact.

Factorial’s cost-effective and innovative in-cell, single-pool technology for NGS library preparation can be used for whole genome and target enrichment sequencing in several key therapeutic applications.

  • Immuno-Oncology

  • Cell & Gene Therapy

  • Targeted Cancer Therapy

  • CRISPR

Immuno-Oncology

  • Understand the composition and dynamics of the tumor microenvironment
  • Characterize cancer cell heterogeneity and assess clonal populations
  • Trace the movement of tumor-infiltrating lymphocytes over time and in response to therapy
  • Neoantigen identification

Cell & Gene Therapy

  • Verify successful transfer of the gene into the intended cell type
  • Characterize and quantify clonal diversity and confirm sequence integrity
  • Post-transplant monitoring of CAR-T cells as a measurement of therapy success

Targeted Cancer Therapy

  • Identify mutations like KRAS and EGFR that contribute to therapy resistance
  • Characterize mutations, gene copy number variation, and co-mutations in single cells
  • Improve patient stratification for clinical studies

CRISPR

  • Quality control for CRISPR, assessing on-target and off-target gene edits
  • Verify successful edit(s) within targeted location in single cells
  • Screen for unintended genomic edits using whole genome sequencing

Let’s realize the potential of single-cell genomics.
Be part of what’s next.

By signing up, you will receive updates on:

  • How extraction-free single-cell sequencing works
  • Applications & use cases
  • How to become an early user
  • When the technology becomes commercially available
favicon

©2023 Factorial Biotechnologies. All rights reserved.